CytomX Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

CytomX Therapeutics

05/08/2025 23:07

CytomX Therapeutics Inc CTMX.OQ CTMX.O is expected to  show a fall in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

The South San Francisco California-based  company is expected to report a 41.2% decrease in revenue to $14.78 million from $25.12 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for CytomX Therapeutics Inc is for a loss of 8 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for CytomX Therapeutics Inc is $5.50, about 56.5% above its last closing price of $2.39

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
0.12
0.12
0.27
Beat
117.7
Dec. 31 2025
-0.15
-0.20
0.23
Beat
217.5
Sep. 30 2024
-0.16
-0.17
0.07
Beat
140.7​
Jun. 30 2024
-0.12
-0.14
-0.08
Beat
44.2
​​Mar. 31 2024
-0.08
-0.08
0.17
Beat
305.2
Dec. 31 2023
0.01
-0.03
0.01
Beat
135​
Sep. 30 2023
-0.15
-0.19
0.04
Beat
121.2
Jun. 30 2023
-0.18
-0.20
-0.02
Beat
90.2

This summary was machine generated August 5 at 22:07 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)